28 th Annual Scientific Meeting

Transcription

1 Value for money in oncology research 28 th Annual Scientific Meeting March 2016 Brisbane Convention & Exhibition Centre Please note this is a Preliminary Program and is subject to changes. Updates will be made as topics, presentations and presenters are confirmed. 1 TROG 2016 ASM Preliminary Program_website version_ docx

2 Tuesday 15 March am 10.30am Opening Session Boulevard Auditorium am Convenor Welcome am Welcome to Country am Official Welcome am President s Report am TSC Update am TCOO Update am am International Guest Speaker: Dr Tito Fojo M.D., Ph.D. The Current Oncology Fantasy: Personalised/Precision Medicine National Guest Speaker: Professor Marion Haas Health Economics am Boulevard Foyer Morning Tea 11.00am 1.00pm Breast SubSpecialty Group Session Boulevard - B1 Chair: Peter Graham am Welcome am am am 11.55am pm pm National Guest Speaker: Dr Nicole Haynes Harnessing the therapeutic potential of radiation therapy with antibody-based immunotherapeutic strategies New trial proposal presentation Category B Randomised phase III trial of adjuvant radiotherapy versus observation following breast conserving surgery and endocrine therapy in patients with molecularly characterized low-risk luminal A early breast cancer Local HER-0: A phase II pilot study of local therapy only (stereotactic radiosurgery and or surgery) for treatment of up to 5 brain metastases from HER2+ breast cancer. HART: Deep Inhalation Breath Hold radiotherapy for patients with left sided breast cancer (STARS): A randomised comparison of anastrozole commenced before and continued during adjuvant radiotherapy for breast cancer versus anastrozole and subsequent antioestrogen therapy delayed until after radiotherapy. 2 TROG 2016 ASM Preliminary Program_website version_ docx

3 pm pm pm pm (PET-LABRADOR): Pet scans for Locally Advanced Breast cancer and diagnostic MRI to determine the extent of Operation and Radiotherapy (DCIS): A randomised phase III study of radiation doses and fractionation schedules for ductal carcinoma in situ (DCIS) of the breast (SUPREMO): A phase III randomised trial to assess the role of adjuvant chest wall irradiation in 'intermediate risk' operable breast cancer following mastectomy. SUPREMO (Selective Use of Postoperative Radiotherapy after MastectOmy) BIG (APBI): A Multicentre Feasibility Study of Accelerated Partial Breast Irradiation Using Three-Dimensional Conformal Radiation Therapy for Early Breast pm (RAPID): Randomized trial of accelerated partial breast irradiation pm Discussion 11.00am 1.00pm Genito-Urinary SubSpecialty Group Session Boulevard - B2 Co-Chairs: David Pryor / Shankar Siva am Welcome am am pm pm pm pm pm New trial proposal: FASTRACK II (Category A) Focal Ablative Stereotactic Radiosurgery for Cancers of the Kidney, a Phase II Clinical Trial. CORE: A multistage multicentre international randomised trial of Conventional care Or Radioablation (stereotactic body radiotherapy) for Extra-cranial oligometastatic disease (CORE) in lung, breast and prostate cancer (RAIDER): A randomised phase II trial of adaptive image guided standard or dose escalated radiotherapy in the treatment of transitional cell carcinoma of the bladder (SPARK): Stereotactic Prostate Adaptive Radiotherapy utilising KIM (Kilovoltage Intrafraction Monitoring) / ANZUP1303 (ENZARAD): Randomised phase 3 trial of radiation plus androgen deprivation therapy with or without enzalutamide for high risk, clinically localised, prostate cancer (RAVES): A phase III multi-centre randomised trial comparing adjuvant radiotherapy (RT) with early salvage RT in patients with positive margins or extraprostatic disease following radical prostatectomy. PSMA-PET directed Oligometastatic Prostate cancer treated with Stereotactic Ablative Radiotherapy to Nodes. (Trial in Development) pm Discussion 11.00am 1.00pm Head & Neck and Skin SubSpecialty Groups Session Boulevard Auditorium Co-Chairs: Chris Wratten 11am 12.15pm June Corry 12.25pm 1pm am Welcome 3 TROG 2016 ASM Preliminary Program_website version_ docx

4 am 11.55am 12.05pm pm pm pm pm pm pm National Guest Speaker: Professor Peter Hersey Challenges for radiotherapy in the anti PD1/PD-L1 era (MP3): A phase II efficacy study of chemo-radiotherapy in PET stage II and III Merkel cell carcinoma of the skin (RTN2): A randomised trial of post operative radiation therapy following wide excision of neurotropic melanoma of the head and neck (WBRT): Whole Brain Radiotherapy following local treatment of intracranial metastases of melanoma-a randomised phase III trial (POST): Post operative concurrent chemo-radiotherapy versus post-operative radiotherapy in high-risk cutaneous squamous cell carcinoma of the head and neck (EORTC1219): A blind randomized multicentre study of accelerated fractionated chemoradiotherapy with or without the hypoxic cell radiosensitizer nimorazole (Nimoral), using a 15- gene signature for hypoxia in the treatment of HPV/p16 negative squamous cell carcinoma of the head and neck (EAT): Eating As Treatment (EAT): An RCT of psychological training for dieticians to reduce malnutrition and depression in head and neck cancer patients undergoing radiotherapy (HPV Oropharynx): A randomised trial of weekly cetuximab and radiation versus weekly cisplatin and radiation in good prognosis locoregionally advanced HPV-associated oropharyngeal squamous cell carcinoma am 1.00pm Lung SubSpecialty Group Session Boulevard B3 Co-Chairs: Fiona Hegi Johnson / David Ball am Welcome am am :50am 11.50am 12.00pm pm pm pm International Guest Speaker: Professor Dirk De Ruysscher Radiotherapy and immune therapy: Good partners? SABR-OS: A phase II randomized trial to test the feasibility of randomizing patients with peripheral stage I non-small cell lung cancer (NSCLC) to either Stereotactic Ablative Radiotherapy (SABR) Or Surgery NivoRAD: Nivolumab vs nivolumab/rt in NSCLC: Randomised phase 2 trial of nivolumab and radiotherapy versus nivolumab alone in advanced non-small cell lung cancer progressing after first line chemotherapy (SAFRON II): Stereotactic Ablative Fractionated Radiotherapy versus radiosurgery for Oligometastatic Neoplasia to the lung: A randomised Phase II trial (PLUNG_GP): Randomised Phase III trial of high dose palliative radiotherapy (HDPRT) vs Concurrent chemotherapy plus HDPRT (C-HDPRT) in good performance status patient with locally advanced or small volume metastatic NSCLC not suitable for radical chemoradiotherapy (CHISEL): A Randomised Phase III trial of highly conformal hypofractionated image guided ( stereotactic ) radiotherapy (hyport) versus conventionally fractionated radiotherapy (conrt) for inoperable early stage I non-small cell lung cancer. National Guest Speaker: Associate Professor Nick Pavlakis Targeted systemic therapies in lung cancer - relevance to radiotherapy pm Discussion: Review of current portfolio 4 TROG 2016 ASM Preliminary Program_website version_ docx

5 pm Lunch Boulevard Foyer pm Afternoon Breast SubSpecialty Group Session Boulevard B1 Chair: Boon Chua pm National Guest Speaker: Professor Sunil Lakhani Review of established and emerging biomarkers in breast cancer pm Discussion: Horizon scanning / New research directions, opportunities and challenges pm Afternoon Genito-Urinary SubSpecialty Group Session Boulevard B2 Co-Chairs: David Pryor / Shankar Siva pm National Guest Speaker: Paul Thomas PSMA PET trials in prostate cancer and renal cell carcinoma pm Human tissues as a focus for GU radiobiology research pm Discussion: Horizon scanning pm Afternoon Head & Neck and Skin SubSpecialty Groups Session Boulevard Auditorium Chair: Chris Wratten pm Interactive session: Horizon Scanning Holes in the portfolio Other Collaborations Where to next pm Afternoon Lung SubSpecialty Group Session Boulevard B3 Chair: Fiona Hegi Johnson pm pm pm New Proposal: DESSERT (Category A) Decision Support Systems for Radiation Therapy in Non-Small Cell Lung Cancer. HALT: Targeted Therapy beyond Progression with or without Dose-intensified RadiotHerapy for Oligo-Progressive Disease in Oncogene-Addicted Lung Tumours. (New Trial Discussion) Discussion: Plugging gaps in the portfolio - Horizon Scanning - Collaboration pm Afternoon Tea Boulevard Foyer 5 TROG 2016 ASM Preliminary Program_website version_ docx

6 Boulevard Auditorium 3.10pm 5.00pm Session Chair: Farshad Foroudi pm (MA.20): A Phase III study of regional radiation therapy in early breast cancer pm National Guest Speaker: Richard De Abreu Lourenço Using health economics in radiotherapy research pm RANZAR: Registry of Australian and New Zealand Ablative Radiotherapy pm pm pm pm pm pm (ROAM): Radiation versus Observation following surgical resection of Atypical Meningioma: a randomised controlled trial (TOPGEAR): A randomised Phase II/III trial of preoperative Chemoradiotherapy versus preoperative chemotherapy for resectable gastric cancer (SCORAD III): A Randomised Phase III study of single fraction radiotherapy compared to multi-fraction radiotherapy in patients with metastatic spinal cord compression (Oesophagus (Dysphagia)): A randomised phase III study in advanced oesophageal carcinoma to compare dysphagia in patients treated with radiotherapy versus chemoradiotherapy (Cervical (FIGO Stage & Tumour Volume)): Prospective Study to Determine the Relationships Between Survival and FIGO Stage, Tumour Volume and Corpus Invasion in Cervical Cancer Primary chemotherapy with temozolomide vs. radiotherapy in patients with low grade gliomas after stratification for genetic 1p loss: a phase III study pm Welcome Dinner - Sponsored by Brainlab Gallery Of Modern Art - Roof Terrace 6 TROG 2016 ASM Preliminary Program_website version_ docx

7 Wednesday 16 March am Breakfast session - Sponsored by Varian Boulevard B1 Boulevard Auditorium 9.00am 9.10am 9.10am 9.20am 9.20am 9.30am 9.30am 9.40am 9.40am 9.50am 9.50am 10.00am 10.00am 10.15am New Proposals Session - Chair: David Christie New Proposal: FASTRACK II (Category A) Focal Ablative Stereotactic Radiosurgery for Cancers of the Kidney, a Phase II Clinical Trial. Discussant 10 mins New Proposal: DESSERT (Category A) Decision Support Systems for Radiation Therapy in Non-Small Cell Lung Cancer. Discussant 10 mins New Proposal: A randomised phase III trial of adjuvant radiotherapy versus observation following breast conserving surgery and endocrine therapy in patients with molecularly characterised low-risk luminal A early breast cancer (Category B) New Proposal: (PLATO)/Anal Cancer Trial 5 (ACT5) PersonaLising Anal cancer RadioTherapy dose (Category B) VESPA - Dosimetric audits for TROG IMRT and VMAT trials using EPID 10.15am 10.25am DATA Mining 10.25am 10.30am Media Matters Promoting your research am Morning Tea Boulevard Foyer am International Guest Speaker: Dr Tito Fojo M.D., Ph.D. Recurrent problems with the design and interpretation of oncology clinical trials 11.45am 1.00pm Annual General Meeting Boulevard Auditorium 1.00pm 1.30pm Lunch Boulevard Foyer 1.30pm 4.30pm Social Afternoon - Afternoon tea at the Convention Centre or the Botanical Gardens 7.00pm 11.00pm Gala Dinner - Sponsored by Elekta Boulevard Room 7 TROG 2016 ASM Preliminary Program_website version_ docx

8 Thursday 17 March am Breakfast session - Sponsored by GenesisCare Boulevard B1 9.00am 1.05pm Boulevard Auditorium - Subspecialty Groups Feedback Sessions Breast SubSpecialty Group Feedback Session - Chair: Verity Ahern am Summary of the TROG portfolio of Breast Studies am Summary of new trial proposals and recommendations of the group am Strategic direction of the group Genito-Urinary SubSpecialty Group Feedback Session - Co-Chairs: David Pryor / Shankar Siva am am GU Session Summary: New trial proposals In development Future directions (TOAD): A collaborative randomized phase III trial: The timing of intervention with androgen deprivation in prostate cancer patients with a rising PSA (Closed) Update - Landmark results am Morning Tea Boulevard Foyer Head & Neck and Skin SubSpecialty Groups Feedback Sessions Co-Chairs: June Corry / Chris Wratten am am Head and Neck Session Summary: Issues with current trials Where to next? Skin Session Summary: Issues with current trials Where to next? Lung SubSpecialty Group Feedback Session - Chair: Fiona Hegi Johnson 11.45am 12.10pm pm Lung Session Summary: new trial proposals and the group s recommendations Issues with current trials Where to next International Guest Speaker: Prof Dirk De Ruysscher Individualized radiotherapy: How biology, physics and genetics meet Closing session pm International Guest Speaker: Dr Tito Fojo A fair price for cancer drugs can be achieved but only if we resolve to make tough decisions 8 TROG 2016 ASM Preliminary Program_website version_ docx

9 pm Close of 2016 ASM Introduction of 2017 ASM Convenor and venue 1.05pm 1.30pm Lunch Boulevard Foyer pm TSC Meeting - by invitation only ASM Additional Meetings Information Monday 14 March TROG-FRO Trainee Statistics & Research Workshop from 8.30am to 5.00pm Room B1 Clinical Research Workshop from 10.00am to 5.30pm Room B2 Technical Research Workshop from 9.30am to 5.30pm Room B3 Tuesday 15 March FROLIC Meeting from 5pm 5.30pm Room B2 Wednesday 16 March TROG Board Meeting from 7.30 to 8.30am Room B2 (by invitation only) TROG Annual General Meeting from 11.45am to 1pm Boulevard Auditorium TROG Publications Committee Meeting lunch time 1pm 1.30pm B2 Thursday 17 March TROG Scientific Committee Meeting from 1.30pm 3.30pm B2 (by invitation only) 9 TROG 2016 ASM Preliminary Program_website version_ docx